[Specific antibody deficiency: Primary immunodeficiency associated to respiratory allergy].

Related Articles

[Specific antibody deficiency: Primary immunodeficiency associated to respiratory allergy].

Rev Chil Pediatr. 2016 Sep 7;

Authors: Fernández F, Campillay R, Palma V, Norambuena X, Quezada A

Abstract
INTRODUCTION: Specific antibody deficiency (SAD) with normal immunoglobulin and normal B cells is a primary immunodeficiency characterized by reduced ability to produce antibodies to specific antigens especially polysaccharides.
OBJECTIVE: To describe the characteristics of patients diagnosed with SAD emphasizing the association between primary immunodeficiency and allergic diseases.
PATIENTS AND METHOD: Descriptive study showing patients with SAD treated at a public hospital between August 2007 and July 2015. Other secondary or primary immunodeficiency was discarded. The diagnosis of SAD was based on recurrent infections and abnormal response to pneumococcal polysaccharide vaccine assessed by specific IgG to 10 pneumococcal serotypes.
RESULTS: Twelve patients were included, 4 males, mean age 6 years, recurrent pneumonia predominated (91.7%) as well as other respiratory and invasive infections. All patients with SAD had associated asthma, 11 had allergic rhinitis, and other allergies. Three patients did not respond to any of the 10 serotypes contained in pneumococcal polysaccharide vaccine, and those who responded were with low titers. Treatment with conjugate pneumococcal vaccine was favorable in 11/12 patients.
CONCLUSION: In children older than 2 years with recurrent respiratory infections or invasive S. pneumoniae infections with normal immunoglobulin we recommend to investigate SAD, especially if they have a concurrent allergic disease.

PMID: 27614984 [PubMed – as supplied by publisher]

View full post on pubmed: asthma

Novel Antibody Demonstrates Promise against Asthma – Genetic Engineering News

Novel Antibody Demonstrates Promise against Asthma
Genetic Engineering News
Scientists at St. Joseph's Healthcare Hamilton and McMaster University report that they successfully tested an antibody (AMG 157) that can improve the quality of life for individuals with asthma by relieving inflammation in the lungs. The study
Amgen drug for allergy asthma shows promise in early testsSFGate
Novel Biologic Promising for Allergic AsthmaMedPage Today
New antibody can improve quality of life for individuals with asthmaNews-Medical.net
Daily Digest –CTV News
all 27 news articles »

View full post on asthma – Google News

Researchers discover new potential antibody treatment for asthma – Medical Xpress


CTV News

Researchers discover new potential antibody treatment for asthma
Medical Xpress
Researchers at St. Joseph's Healthcare Hamilton and McMaster University have successfully tested an antibody that can improve the quality of life for individuals with asthma by relieving inflammation in the lungs. The research was led by Dr. Gail
Canadian researchers find new way to treat mild asthmaCTV News
Hamilton researchers discover potential asthma treatmentHamilton Spectator

all 3 news articles »

View full post on asthma – Google News

Biocentury: Regeneron using Interleukin Antibody Receptors for Asthma … – OneMedPlace (blog)

Biocentury: Regeneron using Interleukin Antibody Receptors for Asthma
OneMedPlace (blog)
An estimated 25 million Americans suffer from Asthma, but current medications such as inhalers have been deemed ineffective for 10-20% of its users. Regneron (REGN) and Sanofi (SAN) have partnered to crease a new Asthma drug, Dupilumab. In their
Clearing The Air On The Sanofi-Regeneron Asthma Drug TrialSeeking Alpha

all 2 news articles »

View full post on asthma – Google News